A genetic analysis of the pharmacokinetic and pharmacodynamic pathways of cetuximab; to assess efficacy and toxicity outcomes in chemotherapy-refractory, metastatic colorectal cancer patients from the Canadian Cancer Trials Group CO.20 and CO.17 trials.
A genetic analysis of the pharmacokinetic and pharmacodynamic pathways of cetuximab; to assess efficacy and toxicity outcomes in chemotherapy-refractory, metastatic colorectal cancer patients from the Canadian Cancer Trials Group CO.20 and CO.17 trials.
西妥昔单抗药代动力学和药效学途径的遗传分析；
批准号：
383355
负责人：
Latifovic Lidija
金额：
$7.65万
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2017
资助国家：
加拿大
项目状态：
已结题
起止时间：
2017-10-01 至 2020-10-01
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Colorectal cancer is the 2nd most common cancer in Canada and many who are diagnosed progress to advanced disease. The use of targeted agents to treat advanced colorectal cancer has improved patient outcomes. Cetuximab is one of the first of these drugs t
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金
